HALOZYME THERAPEUTICS INC
NASDAQ: HALO (Halozyme Therapeutics, Inc.)
Last update: 4 hours ago67.82
0.74 (1.10%)
| Previous Close | 67.08 |
| Open | 67.34 |
| Volume | 1,000,252 |
| Avg. Volume (3M) | 1,743,196 |
| Market Cap | 8,034,927,104 |
| Price / Earnings (TTM) | 26.49 |
| Price / Earnings (Forward) | 4.75 |
| Price / Sales | 5.72 |
| Price / Book | 156.52 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | 44.76% |
| Operating Margin (TTM) | 53.44% |
| Diluted EPS (TTM) | 3.76 |
| Quarterly Revenue Growth (YOY) | 35.20% |
| Quarterly Earnings Growth (YOY) | 53.70% |
| Total Debt/Equity (MRQ) | 318.67% |
| Current Ratio (MRQ) | 8.39 |
| Operating Cash Flow (TTM) | 503.86 M |
| Levered Free Cash Flow (TTM) | 402.43 M |
| Return on Assets (TTM) | 18.50% |
| Return on Equity (TTM) | 147.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Halozyme Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -4.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.40 |
|
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.11% |
| % Held by Institutions | 101.53% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Snyder Capital Management L P | 31 Dec 2025 | 2,399,188 |
| William Blair Investment Management, Llc | 31 Dec 2025 | 1,842,956 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Benchmark, 32.70%) | Buy |
| Median | 82.50 (21.65%) | |
| Low | 75.00 (Wells Fargo, 10.59%) | Hold |
| Average | 82.50 (21.65%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 72.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Benchmark | 19 Feb 2026 | 90.00 (32.70%) | Buy | 72.04 |
| Wells Fargo | 19 Feb 2026 | 75.00 (10.59%) | Hold | 72.04 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| TORLEY HELEN | - | 64.95 | -40,000 | -2,597,800 |
| Aggregate Net Quantity | -40,000 | |||
| Aggregate Net Value ($) | -2,597,800 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 64.95 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TORLEY HELEN | Officer | 02 Apr 2026 | Automatic sell (-) | 20,000 | 64.49 | 1,289,800 |
| TORLEY HELEN | Officer | 02 Apr 2026 | Option execute | 20,000 | - | - |
| TORLEY HELEN | Officer | 01 Apr 2026 | Automatic sell (-) | 20,000 | 65.40 | 1,308,000 |
| TORLEY HELEN | Officer | 01 Apr 2026 | Option execute | 20,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 28 Jan 2026 | Announcement | Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance |
| 20 Jan 2026 | Announcement | Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |